RESUMO
We compared healthcare expenditure over a six-month period following initiation of therapy with either venlafaxine (immediate and extended-release) or a selective serotonin reuptake inhibitor (SSRI) in depressed patients with or without anxiety. Patients beginning treatment for a new depressive episode were identified retrospectively using the administrative data of the MEDSTAT MarketScan database for the period 1994-1999. Before beginning therapy, patients prescribed venlafaxine had more non-mental illnesses (0.85 vs 0.76; p<0.01) and hospitalisations for mental illness (0.53 vs 0.29; p<0.05) than patients prescribed SSRIs. In the six months after initiating treatment, venlafaxine was associated with lower hospitalisation expenditure for non-mental illness ($177 vs $526; p<0.01) than SSRIs, although total healthcare expenditure was not significantly different. Venlafaxine was associated with a 50% decrease in the odds of hospitalisation for non-mental illness compared with SSRIs, with significantly lower inpatient expenditure.
Assuntos
Ansiedade/economia , Cicloexanóis/uso terapêutico , Depressão/economia , Gastos em Saúde/estatística & dados numéricos , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Adolescente , Adulto , Idoso , Ansiedade/tratamento farmacológico , Cicloexanóis/economia , Bases de Dados Factuais , Depressão/tratamento farmacológico , Custos de Medicamentos , Feminino , Custos Hospitalares , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Análise de Regressão , Estudos Retrospectivos , Inibidores Seletivos de Recaptação de Serotonina/economia , Estados Unidos , Cloridrato de VenlafaxinaRESUMO
Growth in utilization rather than price, particularly since 1994, has been the primary driver of increased pharmaceutical spending. In this paper I focus on four factors that have increased utilization, even as cost containment efforts have flourished: (1) "the importance of being unimportant"; (2) increased third-party prescription drug coverage; (3) the introduction of successful new products; and (4) aggressive technology transfer and marketing efforts by pharmaceutical firms. I also consider the roles that these four factors are likely to play in the future.
Assuntos
Controle de Custos/tendências , Indústria Farmacêutica/tendências , Uso de Medicamentos/tendências , Centers for Medicare and Medicaid Services, U.S. , Indústria Farmacêutica/economia , Indústria Farmacêutica/organização & administração , Cobertura do Seguro , Seguro de Serviços Farmacêuticos , Transferência de Tecnologia , Estados UnidosRESUMO
This study examines the differential medical care use and work productivity of employees with and without anxiety and with other mental disorders at a large national firm. A unique aspect of this study is that we integrate medical claims and employer-provided, objective productivity data for the same employees. We find extensive mental health comorbidities among anxious employees. Although medical care use differs considerably among employees having no, one, or several treated mental disorders, in most cases their annual average absenteeism and average at-work productivity performance do not differ. Differences among subgroups are observed for job tenure and maternity claims. We discuss these long-term average productivity findings in relation to other literature encompassing shorter time periods.
Assuntos
Efeitos Psicossociais da Doença , Eficiência , Planos de Assistência de Saúde para Empregados/estatística & dados numéricos , Gastos em Saúde/estatística & dados numéricos , Transtornos Mentais/economia , Absenteísmo , Adulto , Ansiedade/economia , Comorbidade , Feminino , Gastos em Saúde/classificação , Humanos , Masculino , Transtornos Mentais/epidemiologia , Pessoa de Meia-Idade , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: Chronic depression starts at an early age for many individuals and could affect their accumulation of "human capital" (i.e., education, higher amounts of which can broaden occupational choice and increase earnings potential). The authors examined the impact, by gender, of early- (before age 22) versus late-onset major depressive disorder on educational attainment. They also determined whether the efficacy and sustainability of antidepressant treatments and psychosocial outcomes vary by age at onset and quantified the impact of early- versus late-onset, as well as never-occurring, major depressive disorder on expected lifetime earnings. METHOD: The authors used logistic and multivariate regression methods to analyze data from a three-phase, multicenter, double-blind, randomized trial that compared sertraline and imipramine treatment of 531 patients with chronic depression aged 30 years and older. These data were integrated with U.S. Census Bureau data on 1995 earnings by age, educational attainment, and gender. RESULTS: Early-onset major depressive disorder adversely affected the educational attainment of women but not of men. No significant difference in treatment responsiveness by age at onset was observed after 12 weeks of acute treatment or, for subjects rated as having responded, after 76 weeks of maintenance treatment. A randomly selected 21-year-old woman with early-onset major depressive disorder in 1995 could expect future annual earnings that were 12%-18% lower than those of a randomly selected 21-year-old woman whose onset of major depressive disorder occurred after age 21 or not at all. CONCLUSIONS: Early-onset major depressive disorder causes substantial human capital loss, particularly for women. Detection and effective treatment of early-onset major depressive disorder may have substantial economic benefits.
Assuntos
Efeitos Psicossociais da Doença , Transtorno Depressivo/economia , Transtorno Depressivo/epidemiologia , Adulto , Idade de Início , Idoso , Censos , Doença Crônica , Transtorno Depressivo/terapia , Método Duplo-Cego , Escolaridade , Feminino , Humanos , Imipramina/uso terapêutico , Renda , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Análise de Regressão , Sertralina/uso terapêutico , Fatores Sexuais , Resultado do Tratamento , Estados UnidosRESUMO
BACKGROUND AND OBJECTIVES: Since conventional randomized clinical trials often do not reflect the real world circumstances of prescribing behavior and patient outcomes, the use of retrospective administrative claims databases (RACD) has become more common in treatment cost comparisons among alternative pharmaceutical compounds. Several recent RACD studies have compared treatment costs for depressed patients prescribed SSRIs such as fluoxetine, sertraline and paroxetine. These cost comparisons have reached mixed conclusions. To begin to explain and reconcile the mixed SSRI cost comparison evidence, we undertake a variety of alternative multivariate analyses using a publicly available RACD. METHODS AND DATA: The 1995 to 1996 data encompasses a time period when all three SSRIs had become well-established agents. We report and compare results from multivariate linear regressions, logistic regressions, ordered probits and sample selectivity models, and examine robustness when adjustments are made for outlier observations and skewed distributions. RESULTS AND CONCLUSIONS: While choice of initial SSRI is nonrandom, the effect of sample selectivity on total depression-related and total health care expenditure is neutral across SSRIs. Although most cost measures are numerically greatest for fluoxetine, depression-related outpatient and hospitalization costs do not significantly differ by choice of initial SSRI. These findings are robust to alternative assumptions, specifications, and procedures. Antidepressant medication costs, however, are significantly higher when fluoxetine is the initial SSRI rather than sertraline or paroxetine, reflecting the larger proportion of fluoxetine patients prescribed a daily dosage of two or more capsules. Both total depression-related and total health care log-transformed costs are significantly lower for sertraline than fluoxetine.
Assuntos
Depressão/tratamento farmacológico , Fluoxetina/economia , Paroxetina/economia , Inibidores Seletivos de Recaptação de Serotonina/economia , Sertralina/economia , Adulto , Idoso , Análise Custo-Benefício , Bases de Dados Factuais , Depressão/economia , Custos de Medicamentos , Feminino , Fluoxetina/uso terapêutico , Custos de Cuidados de Saúde , Humanos , Revisão da Utilização de Seguros , Masculino , Pessoa de Meia-Idade , Paroxetina/uso terapêutico , Análise de Regressão , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Sertralina/uso terapêutico , Estados UnidosRESUMO
We examined the effects on work productivity of treatment with antihistamines in a retrospective study using linked health claims data and daily work output records for a sample of nearly 6000 claims processors at a large insurance company, between 1993 and 1995. We explained the variation in work output depending on the subjects' demographic characteristics, their jobs, and whether they were treated with "sedating" versus "nonsedating" antihistamines for nasal allergies. Differences of up to 13% in productivity were found after the subjects took sedating or nonsedating antihistamines. The observed effect suggests substantial indirect economic costs, which up to now have been largely overlooked because work productivity has proved difficult to measure objectively.
Assuntos
Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Hipersensibilidade Respiratória/tratamento farmacológico , Perfil de Impacto da Doença , Fases do Sono , Avaliação da Capacidade de Trabalho , Absenteísmo , Adolescente , Adulto , Fatores Etários , Eficiência/efeitos dos fármacos , Feminino , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Análise de Regressão , Estudos Retrospectivos , Medição de Risco , Fatores Sexuais , Estados Unidos , Local de TrabalhoRESUMO
OBJECTIVE: To compare depression-related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline, paroxetine, or fluoxetine. PATIENTS AND METHODS: Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995, following an antidepressant medication-free period of at least 6 months, were included. Treatment course and associated depression-related treatment and total healthcare costs during the subsequent 12-month treatment period were examined using univariate and multivariate methods. RESULTS: Nine-hundred five (905) patients taking sertraline, 492 on paroxetine, and 945 on fluoxetine met inclusion criteria. The groups were similar and representative with respect to gender and age. Mean dose over the 12-month treatment period increased 24%, indicating significant titration in all cohorts. Patients treated with paroxetine had shorter treatment duration (157.0 days) than did patients treated with fluoxetine (192.6 days) or sertraline (166.9 days, P < 0.001). Patients receiving index treatment with paroxetine were most likely to switch to another SSRI (21.3%); those taking sertraline were second most likely to switch (16.1%); and those on fluoxetine were least likely (12.4%, P = 0.001). Mean costs for depression-related outpatient visits and hospitalizations were similar. Mean antidepressant prescription costs differed, being $586, $419, and $446 for fluoxetine, paroxetine and sertraline cohorts, respectively (P < 0.001). In this sample, the fluoxetine cohort did not have lower nonpharmaceutical healthcare costs to offset higher pharmaceutical acquisition costs. Conclusions from median and multivariate analyses were robust to these findings. CONCLUSIONS: During this study period when fluoxetine, paroxetine, and sertraline were all well-established agents, similar depression-related treatment courses and cost characteristics among all 3 drugs were observed.
Assuntos
Antidepressivos de Segunda Geração/economia , Antidepressivos/economia , Transtorno Depressivo/economia , Fluoxetina/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Paroxetina/economia , Inibidores Seletivos de Recaptação de Serotonina/economia , Sertralina/economia , Adolescente , Adulto , Idoso , Antidepressivos/uso terapêutico , Antidepressivos de Segunda Geração/uso terapêutico , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Transtorno Depressivo/tratamento farmacológico , Feminino , Fluoxetina/uso terapêutico , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Paroxetina/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Sertralina/uso terapêutico , Estados UnidosRESUMO
BACKGROUND: We assess the annual economic burden of anxiety disorders in the United States from a societal perspective. METHOD: Using data from the National Comorbidity Study, we applied multivariate regression techniques to calculate the costs associated with anxiety disorders, after adjusting for demographic characteristics and the presence of comorbid psychiatric conditions. Based on additional data, in part from a large managed care organization, we estimated a human capital model of the societal cost of anxiety disorders. RESULTS: We estimated the annual cost of anxiety disorders to be approximately $42.3 billion in 1990 in the United States, or $1542 per sufferer. This comprises $23.0 billion (or 54% of the total cost) in nonpsychiatric medical treatment costs, S13.3 billion (31%) in psychiatric treatment costs, $4.1 billion (10%) in indirect workplace costs, $1.2 billion (3%) in mortality costs, and $0.8 billion (2%) in prescription pharmaceutical costs. Of the $256 in workplace costs per anxious worker, 88% is attributable to lost productivity while at work as opposed to absenteeism. Posttraumatic stress disorder and panic disorder are the anxiety disorders found to have the highest rates of service use. Other than simple phobia, all anxiety disorders analyzed are associated with impairment in workplace performance. CONCLUSION: Anxiety disorders impose a substantial cost on society, much of which may be avoidable with more widespread awareness, recognition, and appropriate early intervention.
Assuntos
Transtornos de Ansiedade/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Adolescente , Adulto , Transtornos de Ansiedade/epidemiologia , Comorbidade , Alocação de Custos , Efeitos Psicossociais da Doença , Custos Diretos de Serviços/estatística & dados numéricos , Custos de Medicamentos/estatística & dados numéricos , Escolaridade , Emprego/economia , Emprego/estatística & dados numéricos , Características da Família , Feminino , Humanos , Masculino , Programas de Assistência Gerenciada/economia , Programas de Assistência Gerenciada/estatística & dados numéricos , Estado Civil , Transtornos Mentais/economia , Transtornos Mentais/epidemiologia , Pessoa de Meia-Idade , Modelos Econômicos , Grupos Raciais , Fatores de Risco , Estados Unidos/epidemiologia , Local de Trabalho/economiaAssuntos
Efeitos Psicossociais da Doença , Custos de Medicamentos , Planos de Assistência de Saúde para Empregados/economia , Antagonistas dos Receptores Histamínicos H1/economia , Eficiência , Antagonistas dos Receptores Histamínicos H1/farmacologia , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Humanos , Hipnóticos e Sedativos/economia , Hipnóticos e Sedativos/farmacologia , Política Organizacional , Estados UnidosRESUMO
OBJECTIVE: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted life-years (QALYs) can provide the basis for an appropriate measure of the value of supportive care interventions. DESIGN: A modelling study drawing cost and effectiveness assumptions from a literature review and from 3 US clinical trials involving more than 4500 patients with cancer who were treated with chemotherapy, radiotherapy, epoetin and blood transfusions as needed under standard care for patients with cancer. MAIN OUTCOME MEASURES AND RESULTS: When compared with transfusions, epoetin is cost effective under varying assumptions, whether effectiveness is measured by haemoglobin level or quality of life. Specifically, under a base-case scenario, the effectiveness resulting from $US1 spent on standard care can be achieved with only $US0.81 of epoetin care. Due in part to the health-state dependence of the significance patients attach to incremental changes in their responses on the linear analogue scale, cost per QALY results are ambiguous in this supportive care context. CONCLUSIONS: Under a broad range of plausible assumptions, epoetin can be used cost effectively in the treatment of anaemic patients with cancer. Further, QALYs have limited applicability here because, as a short term supportive treatment, epoetin enhances the quality but not the length of life. Future research would benefit from the establishment of consistent values for quality-of-life changes across patients and health status, and the extension of the QALY framework to supportive care.
Assuntos
Anemia/tratamento farmacológico , Eritropoetina/economia , Eritropoetina/uso terapêutico , Neoplasias/terapia , Anos de Vida Ajustados por Qualidade de Vida , Anemia/economia , Anemia/etiologia , Terapia Combinada , Análise Custo-Benefício , Humanos , Neoplasias/complicações , Neoplasias/economia , Medição da Dor , Ensaios Clínicos Controlados Aleatórios como Assunto , Proteínas RecombinantesRESUMO
Utilizing data from a clinical trial and an econometric model incorporating the impact of a medical intervention and regression to the mean, we present evidence supporting the hypotheses that for chronically depressed individuals: (i) the level of perceived at-work performance is negatively related to the severity of depressive status; and (ii) a reduction in depressive severity improves the patient's perceived work performance. Improvement in work performance is rapid, with about two-thirds of the change occurring already by week 4. Those patients having the greatest work improvement are those with both relatively low baseline work performance and the least severity of baseline depression.
Assuntos
Depressão/terapia , Eficiência , Avaliação de Desempenho Profissional , Nível de Saúde , Doença Crônica , Depressão/economia , Depressão/fisiopatologia , Humanos , Modelos Econométricos , Índice de Gravidade de Doença , Estados Unidos , Local de TrabalhoRESUMO
Using insurance claims data from nine large self-insured employers offering 26 alternative health benefit plans, we examine empirically how the composition and utilization for the treatment of depression vary under alternative organizational forms of insurance (indemnity, preferred provider organization networks, and mental health carve-outs), and variations in patient cost-sharing (copayments for psychotherapy and for prescription drugs). Although total outpatient mental health and substance abuse expenditures per treated individual do not vary significantly across insurance forms, the depressed outpatient is more likely to receive anti-depressant drug medications is preferred provider organizations and carve-outs than when covered by indemnity insurance. Those individuals facing higher copayments for psychotherapy are more likely to receive anti-depressant drug medications. For those receiving treatment, increases in prescription drug copayments tend to increase the share of anti-depressant drug medication costs accounted for by the newest (and more costly) generation of drugs, the selective serotonin reuptake inhibitors.
Assuntos
Custo Compartilhado de Seguro , Depressão/economia , Depressão/terapia , Seguro Psiquiátrico/economia , Antidepressivos/uso terapêutico , Área Programática de Saúde , Efeitos Psicossociais da Doença , Depressão/epidemiologia , Humanos , Programas de Assistência Gerenciada/economia , Análise Multivariada , Prevalência , Psicoterapia , Estados Unidos/epidemiologiaRESUMO
We analyzed the relationship between depression and patient-assessed or clinician-rated work performance among chronically depressed patients followed for 12 weeks in a large clinical trial. The data were collected in a double-blind design comparing sertraline, a selective serotonin reuptake inhibitor, with imipramine, a tricyclic antidepressant, in 12 academic centers nationwide. Incorporating work-related questions from a portfolio of rating scales used to assess depression, we constructed several measures of work performance, assessed at baseline and at Week 12 of the clinical investigation, and examined how they changed with improvement in depressive symptoms. As depressive symptoms subsided following treatment, patients reported substantial improvement in our measures of work performance. Eighty-six percent of the cohort reported some improvement from base-line to Week 12. The extent of improvement in work performance correlates highly with improvement in the depressive symptoms measured on the Hamilton Rating Scale for Depression. Treatment of depression with antidepressant medications resulted in substantial improvement in subjective work performance among the patients studied.
Assuntos
1-Naftilamina/análogos & derivados , Antidepressivos/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Imipramina/uso terapêutico , 1-Naftilamina/uso terapêutico , Doença Crônica , Transtorno Depressivo/psicologia , Humanos , Escalas de Graduação Psiquiátrica , Sertralina , Análise e Desempenho de TarefasRESUMO
BACKGROUND: We estimate in dollar terms the economic burden of depression in the United States on an annual basis. METHOD: Using a human capital approach, we develop prevalence-based estimates of three major cost-of-illness categories: (1) direct costs of medical, psychiatric, and pharmacologic care; (2) mortality costs arising from depression-related suicides; and (3) morbidity costs associated with depression in the workplace. With respect to the latter category, we extend traditional cost-of-illness research to include not only the costs arising from excess absenteeism of depressed workers, but also the reductions in their productive capacity while at work during episodes of the illness. RESULTS: We estimate that the annual costs of depression in the United States total approximately $43.7 billion. Of this total, $12.4 billion-28%-is attributable to direct costs, $7.5 billion-17%-comprises mortality costs, and $23.8 billion-55%-is derived from the two morbidity cost categories. CONCLUSION: Depression imposes significant annual costs on society. Because there are many important categories of cost that have yet to be estimated, the true burden of this illness may be even greater than is implied by our estimate. Future research on the total costs of depression may include attention to the comorbidity costs of this illness with a variety of other diseases, reductions in the quality of life experienced by sufferers, and added out-of-pocket costs resulting from the effects of this illness, including those related to household services. Finally, it may be useful to estimate the additional costs associated with expanding the definition of depression to include individuals who suffer from only some of the symptoms of this illness.
Assuntos
Efeitos Psicossociais da Doença , Transtorno Depressivo/economia , Custos de Cuidados de Saúde , Absenteísmo , Adolescente , Adulto , Idoso , Assistência Ambulatorial/economia , Transtorno Bipolar/economia , Transtorno Bipolar/epidemiologia , Transtorno Bipolar/terapia , Criança , Comorbidade , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/terapia , Economia , Eficiência , Custos de Saúde para o Empregador , Feminino , Hospitalização/economia , Humanos , Masculino , Pessoa de Meia-Idade , Honorários por Prescrição de Medicamentos , Prevalência , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: To illustrate the burden depression imposes on society, we present estimates of the annual costs of depression--$44 billion--as well as the number of individuals it affects per year--almost 11 million. Although these estimates point to depression as a major illness, this study examines why it is not generally considered as such by the medical and public health communities or by society at large. METHOD: We develop a framework that compares depression with major illnesses such as coronary heart disease, cancer, and AIDS by highlighting salient characteristics of each illness. This comparative illness framework considers the costs, prevalence, distribution of sufferers, mortality, recognition, and treatability of each disease. This comparison underscores many of the similarities and differences among the illnesses examined. RESULTS: Because depression often is not properly recognized and begins to affect many people at a relatively early age, it exacts costs over a longer period of time and in a more subtle manner than other major illnesses. It also imposes a particularly heavy burden on employers in the form of higher workplace costs. CONCLUSION: We conclude that, because of the potential for successful treatment, increased attempts to reach untreated sufferers of depression appear to be warranted. Employers as a group have a particular incentive to invest in the recognition and treatment of this widespread problem, in order to reduce the substantial costs it imposes upon them each year.